Description
What It Is
CJC-1295 (also known as DAC:GRF) is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH) with a drug affinity complex (DAC) — a maleimido-propionic acid moiety that facilitates covalent binding to circulating albumin. This albumin attachment dramatically extends the compound’s half-life from minutes (as seen with native GHRH) to approximately 6–8 days in preclinical models, enabling sustained elevation of GH secretion rather than discrete pulses.
This pharmacokinetic profile distinguishes CJC-1295 from its DAC-free counterpart (Modified GRF 1-29 / CJC-1295 No DAC), which produces short-duration GH pulses that more closely mirror endogenous release dynamics.
Who It’s For
Researchers studying sustained GH axis stimulation, GHRH receptor pharmacology, and comparative pharmacokinetics between short- and long-acting GHRH analogs. CJC-1295 is used in studies where prolonged GH elevation is the experimental objective rather than pulsatile release modeling.
Key Research Applications
- Sustained GH secretion via albumin-mediated half-life extension
- GHRH receptor agonism and downstream pituitary signaling
- Comparative pharmacokinetics vs. native GHRH and CJC-1295 No DAC
- GH axis studies in animal models requiring extended observation periods
Handling & Reconstitution
Store lyophilized CJC-1295 at -20°C, protected from light. Reconstitute with a suitable sterile solvent. The peptide is water-soluble. Once reconstituted, store at 4°C and use within 30 days. Aliquot before freezing to preserve integrity across extended studies.
—
Disclaimer: For research use only. Not for human or veterinary use. Not approved by the FDA. 18+
